0000000000162833

AUTHOR

Kirsten C Spindeldreier

showing 3 related works from this author

Loading, release and stability of epirubicin-loaded drug-eluting beads.

2015

Purpose The aim of this study was to determine the loading efficiency, physico-chemical stability and release of epirubicin-loaded DC Bead™ (Biocompatibles UK Ltd, a BTG International group company) (bead size 70–150 µm (=DC Bead M1™) and 100–300 µm) after loading with epirubicin solution (2 mg/ml) or reconstituted powder formulation (25 mg/ml) and controlled storage. Methods DC Bead™ were loaded with 76 mg epirubicin solution (Epimedac™, Medac GmbH) or 75 mg epirubicin powder formulation (Farmorubicin™, Pharmacia Pfizer GmbH) per 2 ml of beads. Drug loading efficiency and stability were determined by measuring the epirubicin concentration in the excess solution after predetermined interval…

Drug CompoundingDrug StorageBead030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineDrug StabilitymedicinePharmacology (medical)Particle SizeChromatography High Pressure LiquidEpirubicinDrug CarriersChromatographyAntibiotics AntineoplasticDrug eluting beadsElutionbusiness.industrySyringesMicrospheresOncology030220 oncology & carcinogenesisvisual_artDrug releasevisual_art.visual_art_mediumPowdersbusinessEpirubicinmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Physicochemical stability of cabazitaxel containing premix solution and diluted infusion solutions

2015

Objectives This study was conducted to investigate the extended physicochemical stability of cabazitaxel containing premix solution and diluted infusion solutions in either 0.9% sodium chloride (NaCl) or 5% glucose (G5) vehicle solution. Methods A stability indicating, reverse phase, high performance liquid chromatography assay with ultraviolet detection was developed and validated. Premix solutions of cabazitaxel were prepared in the original vials. Infusion solutions were prepared in prefilled polypropylene/polyethylene (PP/PE) infusion bags (0.9% NaCl, G5) to achieve the recommended minimum and maximum cabazitaxel concentrations (0.1 mg/mL, 0.26 mg/mL). Test solutions were stored refrige…

Polypropylenemedicine.medical_specialtyChromatographyInfusion solutionChemistrySodiumchemistry.chemical_elementPolyethyleneHigh-performance liquid chromatographySurgerychemistry.chemical_compoundCabazitaxelmedicinePhysical stabilityGeneral Pharmacology Toxicology and PharmaceuticsQuantitative analysis (chemistry)medicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions.

2013

Objectives The aim of this study was to determine the stability of commercially available eribulin mesylate containing injection solution as well as diluted ready-to-administer solutions stored under refrigeration or at room temperature. Methods Stability was studied by a novel developed stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) assay with ultraviolet detection (detection wavelength 200 nm). Triplicate test solutions of eribulin mesylate containing injection concentrate (0.5 mg/mL) and with 0.9% sodium chloride solution diluted ready-to-administer preparations (0.205 mg/mL eribulin mesylate in polypropylene (PP) syringes, 0.020 mg/mL eribulin mesyl…

Eribulin MesylateChromatographybusiness.industryReproducibility of ResultsInjection solutionPharmacologyKetonesHigh-performance liquid chromatographyPharmaceutical SolutionsOncologyDrug StabilityMedicinePharmacology (medical)Chemical stabilitybusinessFuransChromatography High Pressure LiquidDrug PackagingJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct